Beyond oncological hyperthermia: Physically drivable magnetic nanobubbles as novel multipurpose theranostic carriers in the central nervous system by Ficiara, E. et al.
molecules
Article
Beyond Oncological Hyperthermia: Physically Drivable
Magnetic Nanobubbles as Novel Multipurpose
Theranostic Carriers in the Central Nervous System
Eleonora Ficiarà 1,*,† , Shoeb Anwar Ansari 1,†, Monica Argenziano 2, Luigi Cangemi 2,
Chiara Monge 2, Roberta Cavalli 2 and Federico D’Agata 1
1 Department of Neurosciences, University of Turin, 10124 Turin, Italy;
shoebanwarmohammedkhawja.ansari@unito.it (S.A.A.); federico.dagata@unito.it (F.D.)
2 Department of Scienza e Tecnologia del Farmaco, University of Turin, 10125 Turin, Italy;
monica.argenziano@unito.it (M.A.); luigi.cangemi@unito.it (L.C.); chiara.monge@edu.unito.it (C.M.);
roberta.cavalli@unito.it (R.C.)
* Correspondence: eleonora.ficiara@unito.it
† These authors contributed equally to this work.
Academic Editor: Luigi Paduano
Received: 31 March 2020; Accepted: 29 April 2020; Published: 30 April 2020


Abstract: Magnetic Oxygen-Loaded Nanobubbles (MOLNBs), manufactured by adding
Superparamagnetic Iron Oxide Nanoparticles (SPIONs) on the surface of polymeric nanobubbles,
are investigated as theranostic carriers for delivering oxygen and chemotherapy to brain tumors.
Physicochemical and cyto-toxicological properties and in vitro internalization by human brain
microvascular endothelial cells as well as the motion of MOLNBs in a static magnetic field were
investigated. MOLNBs are safe oxygen-loaded vectors able to overcome the brain membranes and
drivable through the Central Nervous System (CNS) to deliver their cargoes to specific sites of interest.
In addition, MOLNBs are monitorable either via Magnetic Resonance Imaging (MRI) or Ultrasound
(US) sonography. MOLNBs can find application in targeting brain tumors since they can enhance
conventional radiotherapy and deliver chemotherapy being driven by ad hoc tailored magnetic fields
under MRI and/or US monitoring.
Keywords: magnetic nanoparticles; nanobubbles; brain barriers; magnetic driving; brain tumors; theranostic
1. Introduction
Magnetic nanocarriers have been extensively investigated as hyperthermic agents in combination
with radiotherapy to treat superficial and deep tumors [1–3]. In particular, Magnetic Fluid Hyperthermia
(MFH) consists of the in situ administration of a stable colloidal suspension of biocompatible
Superparamagnetic Iron Oxide Nanoparticles (SPIONs) which can produce endogenous heat generation
following activation by external magnetic fields [4]. Clinical applications of MFH has been approved
by the Food and Drug Administration (FDA) and is already marketed (MagForce ® activated by MFH
® 300F or NanoActivator ®).
As tumor oxygenation is one of the main targets of the hyperthermic treatment, our group
investigated the use of oxygen carriers “decorated” by SPIONs as hyperthermic agent [5], showing
that in addition to heating (temperature increase of some ◦C could be reached already at low magnetic
field) such Magnetic Oxygen-Loaded Nanobubbles (MOLNBs) are easily internalized by cells, do not
produce toxic effects, deliver oxygen in a sustained way, and can be monitored either by using clinical
Ultrasound (US) sonography and by Magnetic Resonance Imaging (MRI) [5].
In the present study we further investigated MOLNBs looking at possible applications besides
hyperthermia, i.e., magnetic driving and delivery systems.
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In particular, the attention was focused on the quantitative methods for engineered nanoparticles
to cross brain barriers and to effectively target the Central Nervous System (CNS) [6]. Various chemical
and physical approaches have been proposed to satisfy the requirement for effective therapy and
imaging [4,7].
As a matter of fact, magnetic nanoparticles have already been proposed to bypass the Blood–Brain
Barrier (BBB) to treat glioblastomas and neurodegenerative diseases [8–12] as well as in regenerative
medicine [13,14] and drug delivery [15,16]. Very recently magnetic nanoparticles have been proposed
as transducers in advanced neuromodulation, via the hysteretic heat when exposed to alternated
magnetic fields [17].
We propose MOLNBs as a new theranostic application for the treatment of cerebral tumors,
based on their ability to carry oxygen (a well-known radiotherapy enhancer) and a proper load of
chemotherapy drugs (doxorubicin and possibly temozolomide) [18]. Indeed, we speculate that they
can be locally delivered to the Cerebro-spinal Fluid (CSF) by spinal injection, magnetically driven
towards the part of the choroid plexus anatomically most proximal to the tumor mass where the drug
and oxygen cargoes are delivered after crossing the barrier from the CSF to the brain interstitial fluids.
Previous imaging by Computed Tomography (CT) and/or MRI can guide the tailoring of the
magnetic field required for optimal driving to the tumor, whereas post-treatment imaging by MRI and
US (when the skull does not shield the target) allows the monitoring of the MOLNBs final concentration.
To assess the feasibility of this innovative delivery approach we investigated whether such
nanocarriers are safe, biocompatible, not cytotoxic, and not hemolytic (in case of systemic administration
or possible interactions with blood). In addition, we evaluated their internalization capability by
human brain microvascular endothelial cells (hBMECs) and, finally, if we can drive the MOLNBs using
proper magnetic fields, which is known to be a weakness of all the similar procedure [19].
Accordingly, together with a specific assessment of the physicochemical and biocompatibility
properties of the MOLNBs, their response to the external magnetic field produced by a permanent
magnet has been investigated via ultrasonic imaging.
2. Results
2.1. Physicochemical Characterization of MOLNBs Formulations
The physicochemical characterization of OLNBs and MOLNBs is reported in Table 1. The negative
value of the zeta potential is the fingerprint of dextran sulfate on the NB surface. The average zeta
potential of SPIONs was measured to be +16.24 mV. The positive charge of SPIONs is appropriate
for binding with negatively charged dextran sulfate polymer shell by electrostatic interactions.
After binding of SPIONs the polymer shell surface reduced its zeta potential by 45%. Other specific
parameters of the OLNBs nanosuspension such as pH, viscosity, and osmolarity were 6.52, 0.98 cP and
354 mOsm, respectively. These parameters were not affected by the presence of SPIONs on the NB
surface. Furthermore, OLNBs showed homogenous size and stability over 3 months.
Table 1. Physicochemical characteristics of different nanocarriers formulations. Data reported as Mean
± Standard Deviation.
Formulation Average Diameter (nm) Polydispersity Index Zeta Potential (mV)
Blank OLNBs 331.6 ± 19.7 0.22 ± 0.10 −35.36 ± 4.16
Fluorescent OLNBs 338.2 ± 13.8 0.24 ± 0.08 −34.24 ± 6.52
MOLNBs 349.2 ± 18.2 0.21 ± 0.01 −20.41 ± 8.60
TEM images both of SPIONs and MOLNBs were acquired at different magnification. The TEM
images of MOLNBs showed a spherical and hollow morphology, with a well contrasted shell, as shown
in Figure 1a. An average diameter of about 350 nm was detected for MOLNBs, confirming DLS
measurements. The SPIONs structure is reported in Figure 1b, showing sizes ranging from 5 to 30 nm.
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Figure 1. (a) TEM images of MOLNBs at different mag ifi . (b) TEM images of SPIONs.
2.2. Hemolytic Activity
MOLNB aqueous s pensions tested at different dil (1:10, 1:1 0, 1:200, 1:400 v/v) did not
present sig ificant hemolytic activity, showing no red blo ll damage in comparison with c ntrol.
These data suggest that this nanoformulation is bioco patible and suitable for potential in vivo
administration without any hemolytic problems.
2.3. Evaluation of MOLNBs Internalization and Toxicity
Confocal microscopy was used to verify whether MOLNBs were internalized by hBMECs. Images
showed that MOLNBs, as well as OLNBs, were significantly internalized by hBMECs (Figure 2).
Cytotoxicity studies underlined very good viability of hBMECs after the treatment with SPIONs,
MOLNBs and OLNBs (Figure 3).
2.4. US Monitoring of MOLNBs in the Magnetic Field
The motion of the MOLNBs, located along the negative z-direction of the coordinate system,
centered in the magnet, whose corresponding magnetization of the MOLNBs is dominated by the
component along the z-axis, is significantly affected by the field. Snapshots at different time intervals
from US imaging showed a different distribution of MOLNBs in the absence and in the presence of the
magnetic field, which exerted a sensible effect driving a clearly detectable motion toward the magnet
and along the axis (see Figure 4).
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dilution ratio 1:100 (a) and 1:200 (b) with the medium. Third and fourth rows: cells were treated with 
MOLNBs in a dilution ratio 1:100 (c) and 1:200 (d) with the medium. First Column: cell nuclei after 
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Figure 2. Confocal images of different formulation of nanocarriers internalized by hBMECs after 4 h
of incubation. First and second rows: cells were treated with blank OLNBs (without SPIONs) in a
dilution ratio 1:100 (a) and 1:200 (b) with the medium. T ird an fourth rows: cells were treated with
MOLNBs in a dilut o ratio 1:100 (c) and 1:200 (d) with the medium. First Column: cell nuclei after
DAPI staining, in blue. Second column: OLNBs and MOLNBs, conjugated with 6-Coumarine, in green.
Third column: cell actin filaments after Rhodamine-Phalloidin staining, in red. Fourth column: merged
images. Magnification: 40×. Calibration bar = 20 µm.
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Figure 4. Snapshots from US imaging of MOLNBs in absence (a) and presence (b) of the magnetic field.
Images were recorded at different time frames (5, 15, 25, 55 sec) from the injection.
3. Discussion
MOLNBs are stable nanosystems showing a well-defined hollow structure, whose shell is densely
decorated by SPIONs, as indicated by TEM analysis. The addition of SPIONs does not significantly
increase neither their average diameter nor the polydispersity index, while the zeta potential is
decreased but the value is still effective in preventing aggregation phenomena. This behavior suggested
a good electrostatic interaction of SPIONs with the negatively charged NB shell. The combination of
SPIONs with NB forming stable nanosystems was previously reported [20].
Furthermore, the surface negative charge makes MOLNBs promising candidates to efficiently
cross the BBB, being the zeta potential a crucial parameter for brain delivery [21–23].
MOLNBs were able to store in the perfluorocarbon core and slowly release oxygen by passive
diffusion gradient, as previously evaluated [5]. The oxygen concentration in the nanoformulation is
related to the gas solubilization capability of perfluoropentane (80 mL O2 for 100 mL perfluoropentane).
Indeed, the MOLNBs nanosuspension was saturated with O2 until reaching a 35 mg/L concentration
in the aqueous media, during the preparation process. In these conditions, our previous study [5]
showed a passive sustained and long-lasting oxygen release at different temperatures.
Interestingly, the versatile and peculiar architecture of MOLNBs can allow the incorporation of
drugs with different chemical properties. In fact, the nanostructure consists of three domains: the
core, the shell and the interface [24]. Their different lipophilicity was exploited for the incorporation
of drugs, enabling high payloads [25–27]. Previously, chemotherapeutic drugs, such as doxorubicin
and paclitaxel, were loaded in polymer-shelled NBs showing good stability and prolonged release
kinetics [28–30]. Moreover, they were intravenously injected in mice without any acute side effects.
The absence of hemolytic activity of MOLNBs is an important aspect, being a key parameter for
assessing the safety of the nanocarrier and biocompatibility, and is strictly required for intravenous
administration in early preclinical development [31,32].
In vitro cytotoxicity assay and confocal microscopy images indicate that MOLNBs interact in a
non-toxic way with hBMECs and are localized in the cytoplasm compartment of the cells, as result
of internalization, even if the uptake mechanisms are still not completely elucidated. These results
highlight the potentiality of MOLNBs to enter in the CNS cells. Furthermore, these data pave the way
for future investigation concerning the ability of MOLNBs to cross brain barriers in an in vitro model.
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The magnetic properties of MOLNBs were already investigated in previous research showing
their superparamagnetic behavior and the possibility of monitoring their concentration in tissue
with MRI [5]. In the same study we were able to prove that also US may be effective in detecting
MOLNBs, due to their vaporizable perfluoropentane core and the density contrast of the SPIONs on
their surface. It is worthy of note that perfluoropentane can undergo to Acoustic Droplet Vaporization
(ADV) phenomenon, when irradiated by US [33]. The ADV favor the liquid to gas phase shift of
perfluoropentane, increasing the US backscattering. The US imaging contrast ability of SPIONs
decorated polymer nanobubbles was previously demonstrated by Luo et al. [34].
Therefore, we manufactured a simple device able to visualize the motion of the MOLNBs in a static
magnetic field with field lines in the direction of injection by sonication. This preliminary magnetic
investigation shows that MOLNBs can be magnetically guided using external permanent magnets.
The above results support our initial speculation, since MOLNBs might be safely administrated
either systemically or locally via intravertebral injection in the CSF, monitoring their concentration by
MRI or sonography. Several studies evaluated the distribution of intrathecally injected nanoparticles
within the CNS, assessing the good ability of administration route via CSF rather than systemic
delivery [35,36]. Interestingly, future investigation will involve the study of MOLNBs stability in real
matrix fluids, such as serum or CSF.
Furthermore, MOLNBs may be magnetically driven towards target membranes, for instance the
one separating CSF and the interstitial fluid of the brain located in the choroid plexus in the brain
ventricles to deliver oxygen and chemotherapy drugs to brain tumors.
Tailoring the driving magnetic field based on the position and dimension of the brain tumor
and the brain membranes to be crossed is a goal particularly challenging. Further investigations are
required to validate such application by computational models based on MRI or CT tumor images
(in silico models) and finally on in vivo animal models.
4. Materials and Methods
All reagents were of analytical grade and obtained from Sigma-Aldrich (St. Louis, MO, USA)
unless otherwise specified. Epikuron 200® was kindly provided by Cargill.
4.1. Synthesis of SPIONs
Fe3O4 nanoparticles were synthesized by a co-precipitation method. In a typical synthesis, 0.99 g
of FeCl2 4H2O and FeCl3 6H2O was dissolved in 50 mL of degassed deionized distilled water in
a conical flask and the temperature was moderately increased to 85 ◦C under continuous nitrogen
purging and stirring at 700 rpm for 45 min. Then, 20 mL of ammonia solution 30% was added dropwise
to the reaction mixture, and after pH reached 12 the reaction followed by stirring at 85 ◦C for 1 h.
After the system reached a precipitation state, it was allowed for cooling and settling of the precipitation
at the bottom of the flask at room temperature. The black colored precipitates were separated from
the supernatant by using a permanent magnet. The precipitate was rinsed with distilled water and
allowed to expose in air for 24 h.
4.2. Preparation of MOLNBs Formulations
Epikuron 200® (2.5% w/w) and palmitic acid as a co-surfactant (0.5% w/w) were dissolved in ethanol.
300 µL of the mixture was added to perfluoropentane (PFP. C5F12) in an ice bath. Then the appropriate
volume of distilled water was added dropwise to the mixture. The system was homogenized for 2 min
by using a high-shear homogenizer (Ultra-Turrax®) until the formation of a nanoemulsion. Thereafter,
the nanoemulsion was saturated with O2 for 10 min. Then, an aqueous solution of dextran sulfate
sodium salt (2% w/w) was added dropwise to form the nanobubbles (NB) polymeric shell under an
oxygen purge. Finally, 2 mg/mL of SPIONs suspension were added to NB under stirring, to obtain
MOLNBs (see Figure 5).
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Figure 5. Sketch of MOLNBs (dextran NB covered with Fe3O4 nanoparticles, not to scale) and relative
multifunctional ap lications as theranostic system in CNS.
For the fluorescent nanocarriers, 6-Coumarine (Sigma-Aldrich) was loaded into the MOLNBs core
upon the addition of the fluorochrome directly to perfluoropentane solution. As a control, blank dextran
shelled-OLNBs were also prepared, without the addition of SPIONs.
4.3. Physicochemical Characterization of MOLNBs
The mean hydrodynamic diameter, polydispersity index (PDI) and zeta potential of the SPIONs
and MOLNBs were measured by dynamic light scattering spectroscopy (DLS) at room temperature.
The samples were diluted with ultrapure water in an electrophoretic cell. Each measured value was
the average of ten reciprocal, an electric field of 15 V/m was used for zeta potential determination.
Photon correlation spectroscopy (PCS) with a scattering angle of 90, temperature of 25 ◦C using a
90 Plus instrument (Brookhaven, NY, USA) was used. The viscosity of the NBs formulation was
determined at 25 ◦C using a capillary viscosimeter. The osmolarity was determined at 25 ◦C using an
osmometer. The morphology of MOLNBs was observed by Transmission Electron Microscopy (TEM)
in conventional mode, by using a JEOL2200FS microscope. The diluted NB aqueous suspensions were
sprayed on the Formwar-coated copper grid and air-dried before observation.
4.4. Physical Stability of MOLNBs
The physical stability of blank OLNBs and MOLNBs was evaluated for up to 12 weeks.
The parameters monitored for stability were average size distribution and surface morphology
(shape of bubbles visualized by using microscopy) of the stored NB formulations at 4 ◦C.
4.5. Determination of Hemolytic Activity
Hemolytic activity of MOLNBs was evaluated on rat blood. Blood was diluted 1:10 with PBS
(pH 7.4). Triton × 1% was used as a positive control, where red blood cell breakage and further release
of hemoglobin occurred. Saline solution (NaCl 0.9% w/v) was used as negative control. 1 mL of all
samples were prepared (1:10, 1:100, 1:200, 1:400 dilution) and incubated for 90 min at 37 ◦C. Then, samples
were centrifuged for 5 min at 2000 rpm and the supernatant analyzed with an ultraviolet-visible
spectrophotometer (DU 730, Beckman Coulter, Fullerton, CA) at λ = 543 nm. The percentage of hemolysis
was calculated using the positive control as 100% hemolysis.
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4.6. Evaluation of MOLNBs Internalization by Human Brain Microvascular Endothelial Cells
Human brain microvascular endothelial cells (hBMECs), provided from Cell Systems (Kirkland,
WA, USA), were cultured in EndoGRO Complete Medium (Merck Millipore), plated in 24-well plates on
glass coverslip (5× 104 cells per well) and incubated for 4h in a 500µL of medium with/without MOLNBs
and OLNBs (dilution 1:100 and 1:200) internalized with 6-Coumarine (Sigma-Aldrich) in a humidified
CO2/air-incubator at 37 ◦C. Fixing was carried out by adding 500 µL of cold paraformaldehyde (PFA,
4%) and by incubating for 15 min at room temperature and rinsing the excess PFA with sterile PBS.
After fixing, 4′,6-diamidino-2-phenylindole (DAPI) and Rhodamine-Phalloidin (R415, Invitrogen™,
Thermo Fisher Scientific, MA, USA) staining reactions were performed to label cells nuclei and the
actin filaments. Fixed cells were kept at 4 ◦C for 24 h and fluorescence images were acquired by a
confocal laser scanning microscope (LSM 900, Carl Zeiss, Oberkochen, Germany) equipped with a 40X
oil immersion objective, obtaining a field view of at least 5 cells. A wavelength of 505 nm was used to
detect MOLNBs and OLNBs, of 565 nm and 460 nm to detect respectively the actin filaments and the
nuclei. Images were processed using the software ImageJ (https://imagej.nih.gov/ij/).
4.7. In Vitro Cytotoxicity Study
The hBMECs cells were used to perform in vitro cytotoxicity test. Cells (800/well) were
seeded in 96-well plates and incubated at 37 ◦C, 5% CO2 for 24 h in EndoGRO Complete Medium.
Then, the cells were treated with OLNBs, SPIONs, MOLNBs, in two different dilutions with medium
(1:100 and 1:200). After 72 h incubation, viable cells were evaluated by 2,3-bis [2-methoxy-4-nitro-
5sulphophenyl]-2Htetrazolium-5carboxanilide (MTT) inner salt reagent at 570 nm, as described by the
manufacturer’s protocol. The control cells were normalized to 100%, and the readings from treated
cells were expressed as percent of cell viability. Eight replicates were used to determine each data point
and four different experiments were performed.
4.8. Magnetic Field
The small tank (see Figure 6), where the MOLNBs were sonicated, was positioned with its
horizontal axis aligned with the axial field along z-direction generated by a permanent cuboid magnet
of neodymium covered with Ni-Cu-Ni with dimensions 50 × 50 × 20 mm3 (https://calamite.org),
inducing a field 1.26−1.29 T. The value of residual magnetization of the permanent magnet is in the
range of 1.00−1.03 × 106 A/m. The field lines were investigated using iron filings showing an intense
magnetic induction almost parallel to the axial direction. Simulations of magnetic field lines were
obtained using the analytical expression of the three-dimensional flux density distribution [13,37].
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and demonstrates their biocompatibility and safety in the case of systemic administration. In 
addition, this nanoformulation might be considered a good starting point for developing a system 
able to cross the brain membranes, main obstacle to enter CNS. Furthermore, our preliminary results 
highlighted the capability of MOLNBs to be magnetically driven. Summarizing, this work opens new 
opportunities to consider MOLNBs in targeting brain tumors since they can deliver oxygen 
(potentiating radiotherapy) and chemotherapy drugs, being driven by ad hoc tailored magnetic fields 
under MRI and/or US monitoring. 
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4.9. US Imaging Monitoring
B-mode US imaging was carried out to investigate the response of MOLNBs to the external
magnetic field due to their excellent echogenicity [5]. MOLNBs at concentration 1 × 1010 NB/mL were
injected in a plastic tank containing demineralized water by means of syringe positioned as indicated
in Figure 6. The plastic tank was made by 3D printer to obtain the dimensions 7.5 × 2 × 3 cm3 to well fit
with the probe dimension. A sketch of the setup is shown in Figure 6a. The experiment was performed
at a temperature of 20 ◦C. MOLNBs were sonicated by an US clinical equipment (MyLab™25Gold
Esaote, Genova, Italy), connected to a linear array transducer (LA523, 7.5 MHz central frequency,
Esaote, Genova, Italy) operating in B-mode using the small parts imaging preset. B-mode cineloops
(60 sec) were acquired and recorded for postproduction both in the absence and in the presence of the
permanent magnet exerting a magnetic force in the direction of injection (see Figure 6b). Snapshots
from cineloops were extracted at different time frames (5, 15, 25, 55 sec) after the initial injection and
compared in the different conditions.
5. Conclusions
Our study provides a complete characterization of the physicochemical properties of MOLNBs
and demonstrates their biocompatibility and safety in the case of systemic administration. In addition,
this nanoformulation might be considered a good starting point for developing a system able to
cross the brain membranes, main obstacle to enter CNS. Furthermore, our preliminary results
highlighted the capability of MOLNBs to be magnetically driven. Summarizing, this work opens
new opportunities to consider MOLNBs in targeting brain tumors since they can deliver oxygen
(potentiating radiotherapy) and chemotherapy drugs, being driven by ad hoc tailored magnetic fields
under MRI and/or US monitoring.
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